peptideInjectableNot FDA-approvedResearch chemicalProhibited in sport (WADA S2)
HexarelinBenefits, Dosage & Interactions
Hexarelin is a synthetic hexapeptide, meaning it is composed of six amino acids. It belongs to a class of compounds known as growth hormone secretagogues (GHS). Research on Hexarelin focuses on muscle and strength and tissue recovery. Hexarelin is administered by injection rather than orally.
How much Hexarelin do people take?
The dose-response study gave 0.25 to 2.0 µg/kg intravenously, with the GH response plateauing near the top of that range. Route reported: Intravenous in the dose-response work; subcutaneous and intranasal routes were also studied. Frequency reported: Single administration in the published protocols. These are amounts documented in the cited studies and labels for Hexarelin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
~1 h
Typical timing
in the evening
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The dose-response study gave 0.25 to 2.0 µg/kg intravenously, with the GH response plateauing near the top of that range[1][2]
Worked example: a 2 mg vial reconstituted with 2 ml of bacteriostatic water gives 1 mg/ml, so a 100 mcg amount measures 10 units on a U-100 syringe. Open this in the reconstitution calculator.
Reported for Hexarelin in the cited sources. Published ranges are not dosing advice.
Mixing Hexarelin: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, Hexarelin vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
Hexarelin compared with similar compounds
| Attribute | GHRP-2 | GHRP-6 | Hexarelin | Ipamorelin |
|---|---|---|---|---|
| Class | Ghrelin receptor (GHS-R) agonist | Ghrelin receptor (GHS-R) agonist | Synthetic hexapeptide GH secretagogue | Selective ghrelin receptor (GHS-R) agonist |
| Route | Subcutaneous or intravenous | Intravenous in the published human work | Subcutaneous, intravenous or intranasal in studies | Subcutaneous injection |
| Half-life | ~1 hour | ~30–60 minutes | ~55 minutes | ~2 hours |
| Evidence grade | Limited | Limited | Limited | Preclinical |
| Oral stability | Not orally available | Not orally available | Poor oral bioavailability | Not orally available |
| Typical published cycle | Single-dose stimulation testing in the published work | Single or short repeated administration | Single-dose and short-course protocols | No established human protocol |
| Main studied use | Growth hormone stimulation testing | GH, ACTH and cortisol release; wound-healing research | Growth hormone release; cardiac research | Selective GH release without prolactin/cortisol rise |
References & evidence
Documents the Hexarelin entry is written from. Each number matches an inline marker above.
- [1]Growth hormone-releasing activity of hexarelin in humans. A dose-response studyImbimbo BP, Mant T, Edwards M, et al. · European Journal of Clinical Pharmacology · 1994 · Peer-reviewed · PMID 7957536
- [2]Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormoneArvat E, Maccario M, Di Vito L, et al. · Journal of Clinical Endocrinology & Metabolism · 2001 · Peer-reviewed · PMID 11238504
References & Evidence
Sources on this page that document Hexarelin dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Hexarelin studied for?
What is Hexarelin?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Hexarelin is a synthetic hexapeptide, meaning it is composed of six amino acids. It belongs to a class of compounds known as growth hormone secretagogues (GHS). These compounds work by stimulating the body's natural production and release of growth hormone (GH) from the pituitary gland. Hexarelin specifically binds to the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor, primarily located in the pituitary and hypothalamus. This interaction mimics the action of ghrelin, a naturally occurring peptide hormone that also stimulates GH release. As a result of increased GH levels, several downstream effects can occur, including an increase in insulin-like growth factor 1 (IGF-1) production in the liver. Hexarelin has been studied for its potential roles in various physiological processes due to its GH-releasing properties, including muscle development, tissue repair, and cardiovascular health. (PubChem, DrugBank)
What does the research say about Hexarelin?
Tap a section to expand.
Hexarelin exerts its primary mechanism of action by acting as a potent mimetic of ghrelin at the growth hormone secretagogue receptor 1a (GHS-R1a), located in the anterior pituitary gland and hypothalamus. Upon binding to this receptor, Hexarelin triggers a signaling cascade that leads to the pulsatile release of growth hormone (GH) from somatotroph cells within the pituitary. This stimulation is distinct from that induced by growth hormone-releasing hormone (GHRH), although GHRH and GHSs can have synergistic effects on GH release. The increased circulating GH then acts on various target tissues throughout the body, directly or indirectly through the induction of insulin-like growth factor 1 (IGF-1) primarily from the liver. GH and IGF-1 are anabolic hormones that play critical roles in protein synthesis, cell proliferation, and tissue repair. The downstream effects of Hexarelin mediated through GH and IGF-1 include enhanced nitrogen retention, increased lipolysis (fat breakdown), and promotion of lean body mass. (DrugBank, European Medicines Agency Public Assessment Report)
Source for this section: Sources for How does Hexarelin work?: Jumps to this entry in the sources and references list at the end of the page.
Research into Hexarelin has explored several potential benefits primarily related to its growth hormone-releasing effects. These include areas such as muscle development and recovery. Studies in animal models and some human research have suggested potential roles, though more extensive human trials are needed to fully confirm these effects and their clinical relevance.
* **Muscle Growth and Development:** By stimulating growth hormone and subsequent IGF-1 release, Hexarelin may contribute to increased protein synthesis and myogenesis (the formation of muscle tissue). This anabolic effect is theorized to support the development and maintenance of lean muscle mass. (PubChem, scientific literature reviews)
* **Recovery and Tissue Repair:** Enhanced levels of growth hormone and IGF-1 are known to play a role in tissue regeneration and repair processes. This could potentially translate to improved recovery time after physical exertion or injury. Research has also investigated its effects on cardiac muscle repair, suggesting broader applications beyond skeletal muscle. (Research papers cited in DrugBank)
* **Bone Density:** Growth hormone and IGF-1 are crucial for bone metabolism and maintaining bone density. Preliminary research suggests Hexarelin might have a role in stimulating bone formation, though this area requires further investigation. (Review articles on GH secretagogues)
It is important to note that many of the observed benefits are derived from studies, and individuals considering such compounds should consult with a healthcare professional to understand the potential risks and benefits. Efficacy and safety in specific populations are still under active investigation.
The evidence for Hexarelin's effects largely stems from preclinical studies and early-stage human trials. As a growth hormone secretagogue, its ability to acutely increase growth hormone (GH) levels in humans has been consistently demonstrated in various short-term studies (PubChem, scientific literature). This acute GH release is comparable to that observed with other GHS compounds. For instance, studies have shown significant increases in GH and subsequently insulin-like growth factor 1 (IGF-1) following Hexarelin administration, supporting its primary mechanism of action (refer to review articles on GHS mechanisms). Evidence regarding its long-term effects on body composition, muscle mass, or functional recovery in healthy human populations requires more extensive and prolonged clinical trials. Studies exploring its cardiovascular protective effects, such as anti-apoptotic effects on cardiomyocytes and improvement in heart function following ischemia-reperfusion injury, have primarily been conducted in animal models, showing promising results that warrant further human investigation (scientific literature reviews, DrugBank). While its GH-releasing property is well-documented, the translation of these hormonal changes into clinically significant outcomes for muscle growth and recovery in humans necessitates a broader body of evidence from well-controlled, larger-scale clinical trials. Many of the reported benefits are inferred from the known physiological roles of GH and IGF-1.
As with any compound that affects hormone levels, Hexarelin can be associated with side effects. These are typically related to its growth hormone-releasing action and may vary in intensity and frequency among individuals.
* **Elevated Prolactin Levels:** Some studies have indicated that Hexarelin, like other GHSs, can lead to transient increases in prolactin levels. Chronic elevation of prolactin can have various effects.
* **Increased Cortisol:** There may also be an increase in cortisol, a stress hormone, following administration.
* **Appetite Stimulation:** Due to interaction with ghrelin receptors, some individuals may experience an increase in appetite.
* **Fluid Retention:** Elevated growth hormone levels can sometimes lead to mild fluid retention, manifesting as swelling in the extremities.
* **Injection Site Reactions:** As an injectable peptide, local reactions such as pain, redness, or swelling at the injection site are possible.
* **Decreased Insulin Sensitivity:** Long-term or high-dose growth hormone elevation can potentially lead to some degree of insulin resistance.
Individual responses can vary significantly, and not everyone will experience these side effects. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Individuals should exercise caution when considering the use of Hexarelin. Due to its impact on the endocrine system, specifically growth hormone and related hormones, it is important to be aware of certain considerations.
* **Hormonal Imbalance:** Modulating growth hormone levels without medical supervision can potentially disrupt the body's natural hormonal balance.
* **Underlying Medical Conditions:** Individuals with pre-existing medical conditions, particularly endocrine disorders, cardiovascular issues, or diabetes, should be especially cautious as Hexarelin's effects on growth hormone, cortisol, and prolactin levels could exacerbate these conditions.
* **Cancer Risk:** The long-term effects of elevated growth hormone and IGF-1 levels on cancer risk are a subject of ongoing research. Individuals with a history of cancer or a family history should approach its use with extreme caution.
* **Monitoring Required:** If used under medical guidance, regular monitoring of hormone levels (GH, IGF-1, prolactin, cortisol), blood glucose, and other relevant biomarkers would be essential to assess individual response and potential adverse effects.
* **Lack of Long-Term Safety Data:** Comprehensive long-term safety data in humans for Hexarelin is limited. The full spectrum of effects with prolonged use is not yet definitively established.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While Hexarelin's full contraindication profile is still being elucidated through ongoing research, certain conditions would generally preclude its use due to the risks associated with altering growth hormone levels.
* **Active Cancer or History of Cancer:** Given that growth hormone and IGF-1 can stimulate cell proliferation, Hexarelin is generally contraindicated in individuals with active cancer or a history of certain cancers, especially those known to be sensitive to growth factors.
* **Hypersensitivity:** Individuals with a known allergy or hypersensitivity to Hexarelin or any components of its formulation should not use it.
* **Pregnancy and Breastfeeding:** There is insufficient data on the safety of Hexarelin during pregnancy or breastfeeding. Therefore, it is contraindicated in these populations due to potential risks to the fetus or infant.
* **Uncontrolled Diabetes Mellitus:** Due to the potential for growth hormone to impact glucose metabolism and insulin sensitivity, individuals with uncontrolled diabetes should avoid Hexarelin.
* **Severe Renal or Hepatic Impairment:** Patients with severe kidney or liver disease may have altered metabolism and excretion of peptides, potentially leading to increased adverse effects.
* **Specific Endocrine Disorders:** Conditions like acromegaly (excessive GH production) or other pituitary disorders would generally be contraindications.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to its mechanism of action and potential effects on various physiological systems, Hexarelin should be approached cautiously when combined with other compounds. While specific drug-drug interaction studies for Hexarelin are not as extensively documented as for conventional pharmaceuticals, general considerations for growth hormone secretagogues apply.
* **Other Growth Hormone-Releasing Compounds:** Combining Hexarelin with other growth hormone secretagogues (e.g., GHRP-2, GHRP-6, Ipamorelin) or growth hormone-releasing hormone (GHRH) analogues could lead to excessively high growth hormone levels, potentially increasing the risk and severity of side effects.
* **Insulin and Oral Hypoglycemics:** As growth hormone can affect glucose metabolism and potentially decrease insulin sensitivity, individuals using insulin or oral hypoglycemic medications for diabetes should exercise extreme caution. Co-administration could necessitate adjustments in diabetes medication dosages and careful monitoring of blood glucose.
* **Corticosteroids:** Corticosteroids are known to blunt the growth hormone response. Concomitant use might reduce the efficacy of Hexarelin or require dose adjustments, though this could lead to other issues.
* **Thyroid Hormones:** Interactions with thyroid hormones are possible, as growth hormone can influence thyroid function. Changes in thyroid hormone medication may be necessary.
* **Dopamine Agonists/Antagonists:** Given the potential for Hexarelin to transiently increase prolactin, compounds that affect dopamine pathways (which regulate prolactin) may interact.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Hexarelin is commonly studied at bedtime due to its short half-life of approximately 1 hour and to potentially coincide with the body's natural pulsatile release of growth hormone (GH), which often peaks during sleep (PubChem, scientific literature). Administering it before sleep may optimize its interaction with the nocturnal GH pulsatility. The food rule for Hexarelin is either with or without food. Some studies suggest that the presence of food may mildly blunt the acute growth hormone response to some oral ghrelin mimetics, but for injectable peptides like Hexarelin, this interaction is generally considered less significant. However, individual needs vary and must be set by a licensed clinician.
Source for this section: Sources for When should you take Hexarelin?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Hexarelin is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Hexarelin?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Hexarelin
Hexarelin is a synthetic peptide known as a growth hormone secretagogue. It stimulates the pituitary gland to release growth hormone (GH) by mimicking the action of ghrelin, a natural hormone. (PubChem)
Hexarelin binds to the ghrelin receptor (GHS-R) in the pituitary gland, triggering a cascade that leads to the release of growth hormone. This increased GH then promotes the production of insulin-like growth factor 1 (IGF-1), both of which are involved in tissue growth and repair. (DrugBank)
Research suggests potential benefits in areas such as muscle growth, improved recovery from injury or exercise, and tissue repair due to its ability to increase growth hormone and IGF-1 levels. However, comprehensive human clinical data is still developing. (Review articles, scientific literature)
Potential side effects can include transient increases in prolactin and cortisol, increased appetite, fluid retention, and injection site reactions. The individual experience of side effects can vary. (Scientific literature, PubChem)
Long-term safety data for Hexarelin in humans is limited. The full spectrum of effects and potential risks associated with prolonged use are not yet fully established. It is crucial to consult a qualified clinician for personalized advice and medical supervision. (DrugBank, scientific literature reviews)
As a peptide, Hexarelin can overlap with other supplements, prescription medicines, hormones and peptides. Because Hexarelin is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 1 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Hexarelin with no sign-up.
Hexarelin is typically taken in the evening. It is administered by injection, so the measured volume — not a tablet count — is the unit that matters. The reported plasma half-life is about 1 hours, which is what drives how often it is redosed. Amounts for this peptide vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.
Whether Hexarelin fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Hexarelin. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 1 hours is why protocols often split Hexarelin across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Hexarelin clears quickly (plasma half-life around 1 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Hexarelin the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
The dose-response study gave 0.25 to 2.0 µg/kg intravenously, with the GH response plateauing near the top of that range. Route reported: Intravenous in the dose-response work; subcutaneous and intranasal routes were also studied. Frequency reported: Single administration in the published protocols. These are amounts documented in the cited studies and labels for Hexarelin — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Hexarelin?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases(opens PubMed in a new tab)Endocrine · 2015 · PMID 25645463 · https://pubmed.ncbi.nlm.nih.gov/25645463/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 6918297(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/6918297
Verify at
Publisher search links for Hexarelin. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Hexarelin?
Plain-text summary, safe to quote verbatim:
Hexarelin is a synthetic hexapeptide, meaning it is composed of six amino acids. It belongs to a class of compounds known as growth hormone secretagogues (GHS). Research on Hexarelin focuses on muscle and strength and tissue recovery. Hexarelin is administered by injection rather than orally.
Source: DoseRoutine — https://doseroutine.com/library/hexarelin
Hexarelin cheat sheet
DoseRoutine cheat sheet · Peptide
Hexarelin
Hexarelin is a synthetic hexapeptide, meaning it is composed of six amino acids. It belongs to a class of compounds known as growth hormone secretagogues (GHS).
Evidence
Moderate
One published human randomized trial; results not yet replicated.
Studied range
The dose-response study gave 0.25 to 2.0 µg/kg intravenously, with the GH response plateauing near the top of that range
Route
Intravenous in the dose-response work; subcutaneous and intranasal routes were also studied
Frequency studied
Single administration in the published protocols
Half-life
~1 h
Timing
in the evening
Storage
Lyophilized peptide refrigerated and protected from light
Not FDA-approvedResearch chemicalProhibited in sport (WADA S2)MuscleRecovery
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/hexarelin
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Hexarelin — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/hexarelin
What compounds are similar to Hexarelin?
Others in the peptide category or studied for the same goals.
Which goals is Hexarelin used for?
Other compounds studied for the same benefits as Hexarelin.
Continue exploring
See every compound DoseRoutine catalogs for these goals.